Highest-materiality recent filing
Abpro Chairman Miles Suk resigns; remains director; $50k consulting payoff
Miles Suk voluntarily resigned as Chairman effective Aug 25, 2026; not due to disagreement.
Abpro Holdings CEO Miles Suk resigns; Fatih Karatas named interim CEO
Miles Suk resigned as CEO effective Aug 19, 2026; remains on board; no disagreement cited.
Nasdaq Listing Council confirms delisting of Abpro Holdings; shares to trade OTC Pink
Council reaffirmed delisting on May 28, 2026 for failing to meet minimum equity standard (Rule 5550(b)(1)) by Feb 16, 2026.
Abpro receives Nasdaq delisting notice for failing minimum equity rule; trading to suspend Feb 23
Nasdaq Panel notified Abpro on Feb 18, 2026 that it failed to demonstrate compliance with Listing Rule 5550(b)(1) by Feb 16 deadline.
Abpro receives Nasdaq delisting notices after board resignations; appoints two independent directors
Directors Eisenberg (Jan 28) and Lee (Jan 30) resigned from board and all committees.
Two directors of Abpro Holdings resign; board to fill vacancies
Anthony D. Eisenberg resigned from Board and all committees on Jan 28, 2026.
Abpro Holdings gets $147K CEO loan for D&O insurance; director replaced
CEO Miles Suk lends $147,000 unsecured to fund D&O insurance premium; 9-month term, 3-month interest-free, then SOFR+2%.
Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72
FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.
Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers
IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.
Abpro Holdings granted Nasdaq extension to regain listing compliance
Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.
Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150
Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.
Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025
Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.
Abpro announces 1-for-30 reverse stock split effective Oct 31, 2025; trading begins Nov 3
Reverse stock split effective 5:01 p.m. ET Oct 31; stock trades split-adjusted from Nov 3 under ticker ABP.
Abpro Holdings to effect 1-for-30 reverse stock split, reducing shares from 81.15M to ~2.7M
Reverse stock split ratio 1:30, effective Oct 31, 2025 at 5:01 p.m. EDT.
Abpro fails to regain compliance with Nasdaq MVPHS and MVLS; hearing Oct 30
Received Notice on Oct 14, 2025 that it did not regain MVPHS ($15M) or MVLS ($50M) compliance by Oct 7 deadline.
Abpro Holdings shareholders approve 1-for-30 reverse stock split at 2025 annual meeting
Stockholders elected Ian McDonald as Class I director with 30,544,989 votes for, 8,122,953 withheld, and 10,863,999 broker non-votes.
Abpro Holdings receives Nasdaq delisting notice for minimum bid price non-compliance
180-day compliance period ended Sep 29, 2025; bid price remained below $1.00.
Abpro Holdings furloughs CMO Robert Markelewicz; termination effective Nov 30, 2025
CMO Robert J. Markelewicz, Jr. furloughed effective Sept 30, 2025; will perform no duties until Nov 30.
Abpro enters consulting agreement with CEO Miles Suk's entity; $300K annual fee, 500K RSUs
BioCelsus International (wholly owned by Miles Suk) hired as consultant for CEO services; annual base fee $300,000 payable bi-weekly.
Abpro Holdings postpones 2025 annual meeting to later date
Board voted to postpone annual meeting originally scheduled for June 17, 2025.
ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.
Abpro amends conversion price definition in Yorkville convertible note to fix scrivener's error
Amendment corrects 'Conversion Price' to lower of $11.50 fixed or 94% of lowest daily VWAP over 5 consecutive trading days.
Abpro Holdings receives Nasdaq deficiency notices: MVPHS below $15M, MVLS below $50M
Received two Nasdaq deficiency notices on April 10, 2025: MVPHS below $15M and MVLS below $50M.
Abpro Holdings restates FY22, FY23, Q3 2024 due to $3.3M liability understatement
Audit committee concluded prior-period financials should no longer be relied upon.
Abpro Holdings receives Nasdaq minimum bid price deficiency notice; 180-day cure period.
Received Nasdaq notice on April 2, 2025, for failure to meet $1.00 minimum bid price requirement.
Abpro shareholders approve >20% stock issuance to Yorkville under SEPA
Special meeting April 8, 2025; quorum of 50.7% of shares represented.
Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025
Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.
Abpro terminates CEO Ian Chan, appoints Miles Suk as new CEO
Ian Chan terminated as CEO and principal executive officer, effective March 3, 2025.
Abpro Holdings adjusts warrant exercise price to $3.83 and redemption trigger to $5.99
Warrant exercise price reduced from $11.50 to $3.83 per share, effective March 5, 2025.
Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.
Abpro celebrates business combination close; raises $10M and secures $50M equity facility
Business combination with ACAB closed Nov 13, 2024; Nasdaq bell ringing ceremony held Dec 12.
Abpro Holdings dismisses Marcum as auditor; engages Wolf & Company; cites material weaknesses
Effective Dec 9, 2024, Abpro dismissed Marcum LLP and engaged Wolf & Company as independent auditor.
Abpro CFO Shahraab Ahmad resigns effective Nov 22, 2024
Shahraab Ahmad notified the company of his resignation as CFO on Nov 21, 2024.
Abpro Holdings completes de-SPAC merger with Abpro Corporation; stock begins trading Nov 14
Merger Consideration ~$500M: ~50M shares issued (39.1M to Abpro shareholders, 10.9M reserved for rollover RSUs/options).
Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14
Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.
All 9 proposals passed with 7,587,598 votes for and 20,710 against (99.7% approval).
ACAB enters forward purchase deal for up to 500K shares; 80.5% of public shares seek redemption
Forward Purchase Agreement with YA II PN for up to 500,000 recycled shares; prepayment from trust at ~$11.28/share.
Atlantic Coastal corrects redemption price to $11.34 per share in Abpro merger
Redemption price per Series A share corrected from $11.28 to $11.34 in connection with Abpro business combination.
ACAB enters non-redemption deal to reduce redemptions up to 124K shares before Abpro vote
Non-redemption agreement with Sandia Investment Management LP covering up to 124,352 shares.
ACAB enters $50M equity line and $5M prepaid advance with Yorkville for post-merger financing
$5M prepaid advance via convertible notes with 8% original issue discount; $3M at merger close, $2M after registration effective and shareholder approval.
Nasdaq delisting determination on Oct 16, 2024 for failure to meet market value of publicly held shares, round lot holders, and minimum publicly held shares requirements.
ACAB files amended S-4, revised Abpro presentation; no new financial specifics
Filed amendment to Registration Statement on Form S-4 with SEC on Oct 9, 2024, for Abpro business combination.
Charter amendment extends business combination deadline from Sep 19 to Oct 19, 2024, with optional further monthly extension to Nov 19, 2024.
ACAB amends Abpro merger to issue 600,601 shares to sponsor in lieu of $2M cash payment
ACAB will issue 600,601 shares of Series A common stock to its sponsor Atlantic Coastal Management II LLC, replacing $2,000,000 of Unpaid SPAC Expenses.
ACAB enters PIPE agreements for $11.2M with Abpro Bio and Celltrion for business combination
Abpro Bio subscribes for 622,467 shares at $10/share ($6.2M total), with $4.2M portion via loan forgiveness.
SPAC extends business combination deadline by one month to Sep 19, 2024
Board extended deadline from August 19, 2024 to September 19, 2024 via resolution on Aug 16, 2024.
Received Nasdaq notice on July 31, 2024 for non-compliance with Listing Rule 5450(a) requiring minimum 400 holders of record.
Atlantic Coastal Acquisition Corp. II extends business combination deadline to August 19, 2024
Board extended the deadline from July 19, 2024 to August 19, 2024 (one month).
Atlantic Coastal Acquisition Corp. II extends business combination deadline to July 19, 2024
Board extended deadline from June 19, 2024 to July 19, 2024.
Nasdaq notifies Atlantic Coastal Acquisition Corp II of non-compliance for late Q1 2024 filing
Received Nasdaq notice on June 3, 2024 for failure to timely file Q1 2024 Form 10-Q (due May 15).
On August 19, 2026, Miles Suk provided notice of his voluntary resignation from his position as the Chief Executive Officer to the Board of Directors of Abpro Holdings, Inc. (the “Company”), effective on such date.
The Board of Directors has appointed Mr. M. Fatih Karatas, 47, to serve as Interim Chief Executive Officer of the Company, effective August 25, 2026.
By: /s/ Miles Suk Name: Miles Suk Title: Chief Executive Officer
On March 7, 2025, Abpro Holdings, Inc. (the “Company”) announced that it had terminated Ian Chan as Chief Executive Officer and principal executive officer of the Company, effective as of March 3, 2025.
On November 21, 2024, Shahraab Ahmad notified Abpro Holdings, Inc., a Delaware corporation (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective November 22, 2024.
On November 6, 2023, the Sponsor appointed Curtis Collar to the Board and the Audit Committee of the Board.
On November 6, 2023, Iqbaljit Kahlon resigned from the Board of Directors (the “Board”), and all committees thereof, of Atlantic Coastal Acquisition Corp. II.
Max materiality 0.90 · Median 0.60 · Most common event other_material